source
- Tempus acquires Personalis for $1.5 billion to expand cancer genomics and MRD testingTempus announced it will purchase Personalis in a transaction valued at $1.5 billion, giving it full ownership of the cancer‑genomics firm. The deal builds on a 2023 partnership where Tempus inves…
- Scribe Therapeutics targets $96 million IPO to fund PCSK9 gene-silencing programScribe Therapeutics, a Bay Area biotech focused on genetic medicines, filed with the SEC outlining plans for an initial public offering on Nasdaq. The company aims to sell 7.1 million shares at $1…